173 related articles for article (PubMed ID: 9275183)
1. p53-independent apoptosis induced by paclitaxel through an indirect mechanism.
Lanni JS; Lowe SW; Licitra EJ; Liu JO; Jacks T
Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9679-83. PubMed ID: 9275183
[TBL] [Abstract][Full Text] [Related]
2. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Woods CM; Zhu J; McQueney PA; Bollag D; Lazarides E
Mol Med; 1995 Jul; 1(5):506-26. PubMed ID: 8529117
[TBL] [Abstract][Full Text] [Related]
3. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
[TBL] [Abstract][Full Text] [Related]
4. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells.
van Bree C; Savonije JH; Franken NA; Haveman J; Bakker PJ
Int J Oncol; 2000 Apr; 16(4):739-44. PubMed ID: 10717242
[TBL] [Abstract][Full Text] [Related]
5. Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.
De Feudis P; Vignati S; Rossi C; Mincioni T; Giavazzi R; D'Incalci M; Broggini M
Neoplasia; 2000; 2(3):202-7. PubMed ID: 10935506
[TBL] [Abstract][Full Text] [Related]
6. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.
Wahl AF; Donaldson KL; Fairchild C; Lee FY; Foster SA; Demers GW; Galloway DA
Nat Med; 1996 Jan; 2(1):72-9. PubMed ID: 8564846
[TBL] [Abstract][Full Text] [Related]
7. Effect of paclitaxel pretreatment on radiation-induced p53-dependent apoptosis.
Kawashima M; Hasegawa M; Hayakawa K; Nasu S; Toda H; Suzuki Y; Mitsuhashi N; Niibe H
Anticancer Res; 1999; 19(6B):5101-10. PubMed ID: 10697517
[TBL] [Abstract][Full Text] [Related]
8. Molecular effects of paclitaxel: myths and reality (a critical review).
Blagosklonny MV; Fojo T
Int J Cancer; 1999 Oct; 83(2):151-6. PubMed ID: 10471519
[TBL] [Abstract][Full Text] [Related]
9. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
10. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Exp Cell Res; 1998 May; 241(1):96-101. PubMed ID: 9633517
[TBL] [Abstract][Full Text] [Related]
13. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
15. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells.
Huang Y; Johnson KR; Norris JS; Fan W
Cancer Res; 2000 Aug; 60(16):4426-32. PubMed ID: 10969788
[TBL] [Abstract][Full Text] [Related]
18. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of taxol in human head and neck tumors.
Gan Y; Wientjes MG; Schuller DE; Au JL
Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
